Breakdown | ||||
Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
14.74M | 622.00K | 240.00K | 934.00K | 605.00K | Gross Profit |
14.74M | 622.00K | -23.95M | 934.00K | -8.54M | EBIT |
-344.18M | -362.25M | -351.30M | -330.28M | -220.88M | EBITDA |
-264.43M | -436.18M | -335.51M | -315.38M | -187.93M | Net Income Common Stockholders |
-413.56M | -583.20M | -417.32M | -349.85M | -224.19M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
149.81M | 266.46M | 107.18M | 317.12M | 96.06M | Total Assets |
382.93M | 504.45M | 362.36M | 468.91M | 221.38M | Total Debt |
42.29M | 726.72M | 723.77M | 645.66M | 275.55M | Net Debt |
-101.14M | 461.27M | 619.13M | 464.56M | 240.63M | Total Liabilities |
871.06M | 1.09B | 812.18M | 712.82M | 339.87M | Stockholders Equity |
-488.13M | -586.99M | -447.33M | -242.17M | -119.81M |
Cash Flow | Free Cash Flow | |||
-398.12M | -397.34M | -436.90M | -307.98M | -173.39M | Operating Cash Flow |
-391.24M | -366.76M | -337.51M | -274.42M | -171.72M | Investing Cash Flow |
-12.25M | -30.47M | 27.30M | -84.89M | -19.81M | Financing Cash Flow |
281.63M | 558.34M | 233.61M | 505.44M | 150.68M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
50 Neutral | $95.46M | ― | -101.50% | ― | 76.24% | 38.67% | |
49 Neutral | $6.90B | 0.02 | -54.05% | 2.46% | 24.91% | -3.14% | |
44 Neutral | $114.38M | ― | -53.54% | ― | 145.37% | 57.01% | |
42 Neutral | $38.57M | ― | -270.20% | ― | 144.50% | -141.91% | |
42 Neutral | $110.00M | ― | -54.21% | ― | -78.55% | -0.92% | |
39 Underperform | $2.41B | ― | 78.99% | ― | 2270.58% | 46.82% |
On February 7, 2025, ImmunityBio’s Compensation Committee approved 2024 executive bonuses for its key officers, reflecting an 80% payout of the target amount, with payments scheduled for March 14, 2025. Additionally, the company announced its 2025 Long-Term Incentive Program, granting stock options and restricted stock units to executives, with awards set to vest over three years, and set new base salary rates effective March 10, 2025.